aXichem’s CEO Torsten Helsing presents the interim report Q3 2023 in a webcasted teleconference
aXichem AB (publ), publishes its interim report for the third quarter of 2023 on Wednesday, November 22, 2023. On the same day at 2:00 p.m., the company invites you to a teleconference with CEO Torsten Helsing.
After the conference, there will be a question-and-answer session. Please note that the presentation is held in Swedish. It is possible to follow the conference via computer or mobile devices.
To register for the web conference, please register via the following link:
https://us06web.zoom.us/webinar/register/WN_Arh8_vK0TH6ymy1usdhJFQ
The number of seats is limited, so we recommend registering well in advance to secure a seat.
After the conference, the teleconference and the presentation material will be available on the company's website, aXichem, and on the Västra Hamnen Corporate Finance channel on YouTube.
The information was submitted, through the care of the contact person below, for publication on 20 November 2023, at 10:30 AM CET.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: torsten.helsing@axichem.se
About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Västra Hamnen Corporate Finance AB is Certified Adviser. More information is available at www.axichem.com.